Oncology Central

Angiokinase inhibitors in non-small-cell lung cancer

0

Angiogenesis is an essential component of tumor growth and metastasis. To date, an anti-VEGF antibody, bevacizumab, in combination with paclitaxel and carboplatin in the first-line setting is the only approved antiangiogenic treatment in non-small-cell lung cancer (NSCLC). Angiokinase inhibitors are oral small-molecule agents. They not only inhibit the VEGF pathway, but also target other important signaling pathways contributing to angiogenesis: the PDGF and FGF pathways.

To view restricted content, please:
Share:

Leave A Comment